Guido Hartmann

Guido Hartmann

Auto-generated profile, based on publicly available information

Guido Hartmann

Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2016 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
JRJörg T Regula
Jörg T Regula
PLPeter Lundh von Leithner
Peter Lundh von Leithner
RFRichard Foxton
Richard Foxton
VBVeluchamy A Barathi
Veluchamy A Barathi
CCChui Ming Gemmy Cheung
Chui Ming Gemmy Cheung
GHGuido Hartmann
Guido Hartmann
Anti‐angiogenic therapies using biological molecules that neutralize vascular endothelial growth factor‐A (VEGF‐A) have revolutionized treatment of retinal vascular diseases including age‐related macular degeneration (AMD). This study reports preclinical assessment of a strategy to enhance anti‐VEGF‐A monotherapy efficacy by targeting both VEGF‐A and angiopoietin‐2 (ANG‐2), a factor strongly upregulated in vitreous fluids of patients with retinal vascular disease and exerting some of its activities in concert with VEGF‐A. Simultaneous VEGF‐A and ANG‐2 inhibition was found to reduce vessel lesion number, permeability, retinal edema, and neuron loss more effectively than either agent alone in a spontaneous choroidal neovascularization (CNV) model. We describe the generation of a bispecific domain‐exchanged (crossed) monoclonal antibody (CrossMAb; RG7716) capable of binding, neutralizing, and depleting VEGF‐A and ANG‐2. RG7716 showed greater efficacy than anti‐VEGF‐A alone in a non‐human primate laser‐induced CNV model after intravitreal delivery. Modification of RG7716's FcRn and FcγR binding sites disabled the antibodies' Fc‐mediated effector functions. This resulted in increased systemic, but not ocular, clearance. These properties make RG7716 a potential next‐generation therapy for neovascular indications of the eye. ![][1] The ratio of angiopoietins ANG‐1 and ANG‐2 regulates vessel quiescence and neoangiogenesis as well as barrier function. It also acts as a switch from health to neovascular eye diseases. EMBO Mol Med (2016) 8: 1265–1288 [1]: /embed/graphic-1.gif

30 April 2019 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
JRJörg T Regula
Jörg T Regula
PLPeter Lundh von Leithner
Peter Lundh von Leithner
RFRichard Foxton
Richard Foxton
VBVeluchamy A Barathi
Veluchamy A Barathi
GMGemmy Cheung Chui Ming
Gemmy Cheung Chui Ming
GHGuido Hartmann
Guido Hartmann

22 May 2017 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
JRJörg T Regula
Jörg T Regula
PLPeter Lundh von Leithner
Peter Lundh von Leithner
RFRichard Foxton
Richard Foxton
VBVeluchamy A Barathi
Veluchamy A Barathi
CCChui Ming Gemmy Cheung
Chui Ming Gemmy Cheung
GHGuido Hartmann
Guido Hartmann
This editorial expression of concern is to alert our readership that the …